DDInter1325 DDInter1082
A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Ofloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Ofloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Ofloxacin {u} (Compound) binds {v} (Gene) SLC22A4
Ofloxacin {u} (Compound) upregulates {v} (Gene) SELL
Ofloxacin {u} (Compound) palliates {v} (Disease) chronic obstructive pulmonary disease
Ofloxacin {u} (Compound) is included by {v} (Pharmacologic Class) Quinolones
Ofloxacin {u} (Compound) downregulates {v} (Gene) RB1
Ofloxacin {u} (Compound) causes {v} (Side Effect) Petechiae
Ofloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pentostatin
Ofloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Procarbazine
Ofloxacin (Compound) resembles Enoxacin (Compound)
Ofloxacin (Compound) resembles Levofloxacin (Compound)
Ofloxacin (Compound) binds SLC22A4 (Gene)
Ofloxacin (Compound) upregulates SELL (Gene)
Ofloxacin (Compound) palliates chronic obstructive pulmonary disease (Disease)
Ofloxacin (Compound) is included by Quinolones (Pharmacologic Class)
Ofloxacin (Compound) downregulates RB1 (Gene)
Ofloxacin (Compound) causes Petechiae (Side Effect)
Ofloxacin may cause a minor interaction that can limit clinical effects when taken with Pentostatin
Ofloxacin may cause a minor interaction that can limit clinical effects when taken with Procarbazine